Biomed Pharmacother:高车前素预防老年大鼠由七氟醚诱发的记忆障碍

2018-08-12 余晓旭 罂粟花

七氟醚作为一种广泛使用的全身麻醉药,发现它可以诱导老年人的认知和记忆障碍。这可能会增加患老年痴呆症AD的风险。本研究探讨了一种天然黄酮类化合物高车前素对七氟醚诱发的记忆功能障碍的神经保护作用。

背景与目的:七氟醚作为一种广泛使用的全身麻醉药,发现它可以诱导老年人的认知和记忆障碍。这可能会增加患老年痴呆症AD的风险。本研究探讨了一种天然黄酮类化合物高车前素对七氟醚诱发的记忆功能障碍的神经保护作用。

方法:利用老龄大鼠模型,对七氟醚在记忆功能上的影响进行了评价。用TUNEL分析方法对大鼠海马体中的凋亡细胞进行了评估。用WB检测海马体中的细胞凋亡相关蛋白质标记物水平。研究还检测了七氟醚和高车前素对Aβ累积的影响。此外,通过测量促炎细胞因子的表达,以及从胞浆到细胞核的Nf-kb p65的易位,评估了高车前素对七氟醚-诱发的神经炎症的衰减效应。在海马体中也发现了Nrf2的激活。此外,还用体外模型研究了高车前素对七氟醚-诱导的细胞凋亡、人类神经胶质瘤H4中Aβ累积和神经炎症的影响。为了进一步研究Nrf2在高车前素对抗七氟醚-神经毒性的神经保护活动中的作用,H4细胞转染了Nrf2靶向siRNA,这导致Nrf2的表达显着减少。

结果:新物体识别和y-迷宫测试结果表明,七氟醚对老年大鼠的记忆有明显的损害,而对大鼠高车前素预处理则明显地改善了大鼠的记忆。从机制方面来说,我们的发现表明,高车前素显着减弱了七氟醚诱导的细胞凋亡、Aβ累积和神经炎症。与在体模型研究结果一致,高车前素也能减弱七氟醚诱导的细胞凋亡,降低增加的Aβ水平,以及改善H4细胞的神经炎症。此外,我们的研究结果表明,Nrf2的激活介导了对七氟醚诱发的神经毒性的神经保护作用,证明了H4细胞敲除Nrf2显着地损害了它的保护作用。

结论:我们的研究提供了体外和在体的证据,证明高车前素可以预防七氟醚引起的神经功能障碍,高车前素有可能成为一种神经保护剂,来改善接受麻醉的老年病人的认知和记忆功能。

原始出处:

Huang L, Huang K, Ning H, et al. Hispidulin prevents sevoflurane— Induced memory dysfunction in aged rats. Biomed Pharmacother. 2018 Jan;97:412-422. doi: 10.1016/j.biopha.2017.10.142.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908457, encodeId=e579190845e30, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jan 31 16:03:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676106, encodeId=524a16e6106b9, content=<a href='/topic/show?id=be5c9135560' target=_blank style='color:#2F92EE;'>#记忆障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91355, encryptionId=be5c9135560, topicName=记忆障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849927326976, createdName=baoya, createdTime=Sat Apr 20 15:03:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787516, encodeId=aca21e87516bb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 23 07:03:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918239, encodeId=c9081918239a5, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 03:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996203, encodeId=0fb919962036b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 11:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412690, encodeId=f268141269004, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609053, encodeId=40aa1609053d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908457, encodeId=e579190845e30, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jan 31 16:03:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676106, encodeId=524a16e6106b9, content=<a href='/topic/show?id=be5c9135560' target=_blank style='color:#2F92EE;'>#记忆障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91355, encryptionId=be5c9135560, topicName=记忆障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849927326976, createdName=baoya, createdTime=Sat Apr 20 15:03:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787516, encodeId=aca21e87516bb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 23 07:03:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918239, encodeId=c9081918239a5, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 03:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996203, encodeId=0fb919962036b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 11:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412690, encodeId=f268141269004, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609053, encodeId=40aa1609053d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908457, encodeId=e579190845e30, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jan 31 16:03:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676106, encodeId=524a16e6106b9, content=<a href='/topic/show?id=be5c9135560' target=_blank style='color:#2F92EE;'>#记忆障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91355, encryptionId=be5c9135560, topicName=记忆障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849927326976, createdName=baoya, createdTime=Sat Apr 20 15:03:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787516, encodeId=aca21e87516bb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 23 07:03:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918239, encodeId=c9081918239a5, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 03:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996203, encodeId=0fb919962036b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 11:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412690, encodeId=f268141269004, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609053, encodeId=40aa1609053d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
    2019-01-23 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908457, encodeId=e579190845e30, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jan 31 16:03:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676106, encodeId=524a16e6106b9, content=<a href='/topic/show?id=be5c9135560' target=_blank style='color:#2F92EE;'>#记忆障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91355, encryptionId=be5c9135560, topicName=记忆障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849927326976, createdName=baoya, createdTime=Sat Apr 20 15:03:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787516, encodeId=aca21e87516bb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 23 07:03:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918239, encodeId=c9081918239a5, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 03:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996203, encodeId=0fb919962036b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 11:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412690, encodeId=f268141269004, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609053, encodeId=40aa1609053d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
    2018-10-17 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1908457, encodeId=e579190845e30, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jan 31 16:03:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676106, encodeId=524a16e6106b9, content=<a href='/topic/show?id=be5c9135560' target=_blank style='color:#2F92EE;'>#记忆障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91355, encryptionId=be5c9135560, topicName=记忆障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849927326976, createdName=baoya, createdTime=Sat Apr 20 15:03:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787516, encodeId=aca21e87516bb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 23 07:03:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918239, encodeId=c9081918239a5, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 03:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996203, encodeId=0fb919962036b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 11:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412690, encodeId=f268141269004, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609053, encodeId=40aa1609053d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
    2018-10-23 yb6560
  6. [GetPortalCommentsPageByObjectIdResponse(id=1908457, encodeId=e579190845e30, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jan 31 16:03:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676106, encodeId=524a16e6106b9, content=<a href='/topic/show?id=be5c9135560' target=_blank style='color:#2F92EE;'>#记忆障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91355, encryptionId=be5c9135560, topicName=记忆障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849927326976, createdName=baoya, createdTime=Sat Apr 20 15:03:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787516, encodeId=aca21e87516bb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 23 07:03:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918239, encodeId=c9081918239a5, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 03:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996203, encodeId=0fb919962036b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 11:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412690, encodeId=f268141269004, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609053, encodeId=40aa1609053d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1908457, encodeId=e579190845e30, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Jan 31 16:03:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676106, encodeId=524a16e6106b9, content=<a href='/topic/show?id=be5c9135560' target=_blank style='color:#2F92EE;'>#记忆障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91355, encryptionId=be5c9135560, topicName=记忆障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849927326976, createdName=baoya, createdTime=Sat Apr 20 15:03:00 CST 2019, time=2019-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787516, encodeId=aca21e87516bb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 23 07:03:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918239, encodeId=c9081918239a5, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 03:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996203, encodeId=0fb919962036b, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Oct 23 11:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412690, encodeId=f268141269004, content=<a href='/topic/show?id=1c2f195092d' target=_blank style='color:#2F92EE;'>#七氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19509, encryptionId=1c2f195092d, topicName=七氟醚)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a102881238, createdName=linagood, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609053, encodeId=40aa1609053d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 14 10:03:00 CST 2018, time=2018-08-14, status=1, ipAttribution=)]

相关资讯

JAMA Psychiatry:读书、下棋、搓麻!香港中文大学团队证实,老年人坚持参与智力活动可使痴呆风险下降三成

近期的《美国医学会杂志-精神病学》(JAMA Psychiatry)上,香港中文大学的研究团队用一项涉及1.5万名中国老人的临床研究,为预防痴呆支了一招:老年人长期参与用脑的业余活动,不管是读书看报还是打牌下棋搓麻将,能使痴呆发病风险下降29%!

Hum Mol Genet:“绕开”淀粉样蛋白,科学家们正在寻找老年痴呆新病因

作为一种常见的神经性衰退疾病,阿尔兹海默症(AD)起病隐袭、多发于中老年群体。不少学者认为,β-淀粉样蛋白是AD一级预防的理想目标。现在,一篇新研究提出了不同的看法,来自于纽约州立大学布法罗分校的科学家们找到了另一种关键蛋白,有望在AD早期防治中发挥作用。

科学家解析疱疹病毒与老年痴呆关系

由于阿尔茨海默氏症进展缓慢,以及收集脑组织样本存在困难,人们对其病因了解仍不透彻。但近日发表在《神经元》杂志上的一项大规模研究报告称,美国西奈山伊坎医学院的研究人员分析了3个不同的大脑数据库,发现人类疱疹病毒在阿尔茨海默氏症患者的大脑中更丰富,可能影响遗传网络协调,这些网络被认为与该疾病有关。这项研究支持了一种有争议的假设,即疱疹病毒与阿尔茨海默氏症有关,并为相关治疗提供了潜在新途径。研究人员分析

Curr Biol:颠覆教条!《Cell》子刊:抗阿尔兹海默症药物或许会加速病情发展!

阿尔兹海默症,又叫老年痴呆,一直困扰世界范围内数以千计的患者,而Tau蛋白对于脑细胞微管的病理生理学作用一直被视为阿尔兹海默症的主要发病机制。医学研究领域一直认为Tau蛋白对于脑细胞微管具有稳定作用,而Peter W. Baas领导的研究团队发现Tau并不具备这种作用,相反,其还有具有不稳定的结构域。这意味着市面上很多治疗阿尔兹海默症的药物或许会加重病情的发展。

Mol Neurobiol:哮喘药可逆转实验鼠老年痴呆

美国坦普尔大学日前发布新闻公报说,该校研究人员发现,哮喘药“齐留通”能缓解实验鼠的老年痴呆现象,恢复其记忆力和学习能力,这为治疗阿尔茨海默病带来了新希望。

涨知识:多学一门外语 可防老年痴呆

痴呆是由脑部疾病所致的综合征,认知损害的程度足以干扰日常生活能力或社会职业功能。老年性痴呆学名阿尔茨海默病,是发生在老年期及老年前期的一种原发性退行性脑病,对老年人的健康和生活影响非常大。